Comparing costs and effectiveness of two diabetes medications with Metformin
Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.
This study is testing whether combining Metformin with either sulfonylureas or DPP4 inhibitors is more cost-effective and effective for people with Type 2 Diabetes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh Academic / other |
| Locations | 1 site (Dhaka) |
| Trial ID | NCT06570980 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the cost-effectiveness of two treatment regimens for Type 2 Diabetes Mellitus (T2DM): one combining Metformin with sulfonylureas and the other with DPP4 inhibitors. It will be a multi-centered, retrospective, observational study involving patients diagnosed with T2DM for 2 to 5 years. The study will compare glycemic control and other clinical outcomes between the two groups, analyzing the incremental cost-effectiveness ratio (ICER) of each treatment approach. Conducted at Bangabandhu Sheikh Mujib Medical University and other centers, it will enroll 206 patients, with 103 in each treatment group.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with new onset Type 2 Diabetes diagnosed for 2 to 5 years, currently taking either sulfonylureas or DPP4 inhibitors combined with Metformin.
Not a fit: Patients on insulin therapy or those who have been on monotherapy with Metformin since diagnosis will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify the more cost-effective treatment option for managing Type 2 Diabetes, potentially reducing the financial burden on patients.
How similar studies have performed: While cost-effectiveness studies in diabetes management are common, this specific comparative analysis of sulfonylureas versus DPP4 inhibitors in combination with Metformin is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * New onset type2 diabetes mellitus diagnosed for 2 -5 years. * Taking either sulfonylurea or DPP4 inhibitors combined with Metformin from the time of diagnosis. * Age 18 years or above. * Both male and female. * Provided written informed consent. Exclusion Criteria: * Unwillingness to participate or unwillingness to give written informed consent. * Patients on Insulin therapy or monotherapy with metformin since the time of diagnosis. * Taking other than sulfonylurea or DPP4 inhibitors combined with Metformin from the time of diagnosis. * Diabetes related complications at the time of diagnosis.
Where this trial is running
Dhaka
- Bsmmu — Dhaka, Bangladesh (Recruiting)
Study contacts
- Principal investigator: Dr. Sheuly Akter, MD — Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Study coordinator: Dr. Sheuly Akter, MD
- Email: dr.sheuly7314@gmail.com
- Phone: +880-1951208001
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.